The COBRRA Study: Shifting Paradigms in Acute VTE Treatment

Send us Fan MailIn this episode of Clot Conversations, Dr. Lana Castellucci, University of Ottawa, discusses the COBRRA study, which compares the bleeding risks of rivaroxaban and apixaban in patients with acute VTE. The study follows patients for three months and finds that apixaban significantly reduces combined bleeding events compared to rivaroxaban. While the trial wasn't powered for individual outcomes, it shows no difference in VTE recurrence. This is potentially practice-changing information, indicating that most acute VTE patients might benefit from apixaban over rivaroxaban, although patient-specific factors and preferences will still play a role in decision-making.Support the showhttps://thrombosiscanada.caRegister today for our upcoming conference on November 7, 2026 in Montreal at https://thrombosiscanada.ca/2026ConferenceTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada